

February 5, 2020



## **Actinium Pharmaceuticals, Inc. to Present at the 22nd Annual BIO CEO & Investor Conference**

**- Presentation scheduled for Tuesday, February 11th at 10:15 am ET**

NEW YORK, Feb. 5, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that Sandesh Seth, Actinium's Chairman & CEO, will be presenting at the 22<sup>nd</sup> Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Innovation Organization (BIO), the 22<sup>nd</sup> Annual BIO CEO & Investor Conference will take place February 10<sup>th</sup> and 11<sup>th</sup> at the New York Marriott Marquis in New York City.



### **Presentation Details**

Date: Tuesday, February 11

Time: 10:15 am ET

Presenter: Sandesh Seth, Chairman and CEO

Location: New York Marriott Marquis, Ziegfeld Room

Members of Actinium's Executive team will be available for one-on-one meetings with conference attendees. Those interested in scheduling a meeting with Actinium may do so by contacting Steve O'Loughlin, Principal Financial Officer via email at [soloughlin@actiniumpharma.com](mailto:soloughlin@actiniumpharma.com).

### **About Actinium Pharmaceuticals, Inc. (NYSE: ATNM)**

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium's lead application for our ARCs is targeted conditioning, which is intended to selectively deplete a patient's disease or cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, Gene Therapy or Adoptive Cell Therapy (ACT) such as CAR-T to enable engraftment of these transplanted cells with minimal toxicities. With our ARC approach, we seek to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted

chemotherapy that is used for conditioning in standard practice currently. Our lead product candidate, apamistamab-I-131 (lomab-B) is being studied in the ongoing pivotal Phase 3 Study of lomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The SIERRA trial is over fifty percent enrolled and promising single-agent, feasibility and safety data has been highlighted at ASH, TCT, ASCO and SOHO annual meetings. Apatmistamamb-I-131 will also be studied as a targeted conditioning agent in a Phase 1/2 anti-HIV stem cell gene therapy with UC Davis and is expected to be studied with a CAR-T therapy in 2020. In addition, we are developing a multi-disease, multi-target pipeline of clinical-stage ARCs targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a broad range of hematologic malignancies including acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Ongoing combination trials include our CD33 alpha ARC, Actimab-A, in combination with the salvage chemotherapy CLAG-M and the Bcl-2 targeted therapy venetoclax. Underpinning our clinical programs is our proprietary AWE (Antibody Warhead Enabling) technology platform. This is where our intellectual property portfolio of over 100 patents, know-how, collective research and expertise in the field are being leveraged to construct and study novel ARCs and ARC combinations to bolster our pipeline for strategic purposes. Our AWE technology platform is currently being utilized in a collaborative research partnership with Astellas Pharma, Inc.

More information is available at [www.actiniumpharma.com](http://www.actiniumpharma.com), [www.sierratrial.com](http://www.sierratrial.com) and our Twitter feed @ActiniumPharma, [www.twitter.com/actiniumpharma](https://www.twitter.com/actiniumpharma).

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.

This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.

## **Contacts:**

Investors:

Hans Vitzthum

LifeSci Advisors, LLC

[Hans@LifeSciAdvisors.com](mailto:Hans@LifeSciAdvisors.com)


(617) 535-7743

Media:

Alisa Steinberg, Director, IR & Corp Comms

[asteinberg@actiniumpharma.com](mailto:asteinberg@actiniumpharma.com)

(646) 237-4087

 View original content to download multimedia <http://www.prnewswire.com/news-releases/actinium-pharmaceuticals-inc-to-present-at-the-22nd-annual-bio-ceo--investor-conference-300999431.html>

SOURCE Actinium Pharmaceuticals, Inc.